PET and SPECT imaging of melanoma: the state of the art.
Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. 18F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.
['Wei|Weijun|W|', 'Ehlerding|Emily B|EB|', 'Lan|Xiaoli|X|', 'Luo|Quanyong|Q|', 'Cai|Weibo|W|']
D000818:Animals D006801:Humans D008545:Melanoma D009362:Neoplasm Metastasis D011485:Protein Binding D019275:Radiopharmaceuticals D015899:Tomography, Emission-Computed, Single-Photon
Melanoma Cancer Molecular imaging Immunotherapy Positron emission tomography (PET) Single-photon emission computed tomography (SPECT) Theranostics